Inhibrx Biosciences (INBX) Liabilities and Shareholders Equity: 2023-2025
Historic Liabilities and Shareholders Equity for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $177.5 million.
- Inhibrx Biosciences' Liabilities and Shareholders Equity fell 20.26% to $177.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $813.0 million, marking a year-over-year change of. This contributed to the annual value of $180.8 million for FY2024, which is 41.29% down from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Liabilities and Shareholders Equity is $177.5 million, which was down 16.33% from $212.1 million recorded in Q2 2025.
- Over the past 5 years, Inhibrx Biosciences' Liabilities and Shareholders Equity peaked at $307.9 million during Q4 2023, and registered a low of $177.5 million during Q3 2025.
- Over the past 3 years, Inhibrx Biosciences' median Liabilities and Shareholders Equity value was $222.6 million (recorded in 2024), while the average stood at $228.8 million.
- Data for Inhibrx Biosciences' Liabilities and Shareholders Equity shows a maximum YoY tumbled of 41.29% (in 2024) over the last 5 years.
- Quarterly analysis of 3 years shows Inhibrx Biosciences' Liabilities and Shareholders Equity stood at $307.9 million in 2023, then tumbled by 41.29% to $180.8 million in 2024, then dropped by 20.26% to $177.5 million in 2025.
- Its Liabilities and Shareholders Equity stands at $177.5 million for Q3 2025, versus $212.1 million for Q2 2025 and $242.6 million for Q1 2025.